{"organizations": [], "uuid": "2ab7d77b44cda86aa3b1248bd789831d714757bc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bellicum-announces-update-on-clini/brief-bellicum-announces-update-on-clinical-hold-of-u-s-bpx-501-studies-idUSASB0C78W", "country": "US", "domain_rank": 408, "title": "BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T14:03:00.000+02:00", "replies_count": 0, "uuid": "2ab7d77b44cda86aa3b1248bd789831d714757bc"}, "author": "", "url": "https://www.reuters.com/article/brief-bellicum-announces-update-on-clini/brief-bellicum-announces-update-on-clinical-hold-of-u-s-bpx-501-studies-idUSASB0C78W", "ord_in_thread": 0, "title": "BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "bellicum pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 04 PM / Updated 8 minutes ago BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies Reuters Staff Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc: * BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES * BELLICUM - RECEIVED NOTIFICATION FROM FDA OUTLINING CRITERIA REQUIRED FOR LIFTING CLINICAL HOLD ON U.S. STUDIES OF BPX-501 * BELLICUM PHARMACEUTICALS INC - CLINICAL HOLD DOES NOT AFFECT COMPANYâ€˜S BP-004 REGISTRATION TRIAL IN EUROPE * BELLICUM - PLANS TO IMPLEMENT REVISIONS TO U.S. STUDY PROTOCOLS, ADDITION OF MORE COMPREHENSIVE MONITORING, MANAGEMENT OF NEUROTOXICITY FOR BPX-501 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-23T14:03:00.000+02:00", "crawled": "2018-02-23T14:20:58.024+02:00", "highlightTitle": ""}